In the Claims

Please add claim 32 and amend claim 31 as follows:

1. (Original) A compound a compound of formula I:



(I)

wherein:

R^1 is an organic releasing group comprising a quinone ring;

R_a, R_b, R_c, and R_d are each independently hydrogen, $(C_1\text{-}C_6)$alkyl, or $-CH_2CH_2X$;

and

each X is independently halo, $(C_1\text{-}C_6)$alkylsulfonyl, halo$(C_1\text{-}C_6)$alkylsulfonyl, or arylsulfonyl, wherein each aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) halo, $(C_1\text{-}C_6)$alkyl, halo$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkanoyl, $(C_1\text{-}C_6)$alkanoyloxy, $(C_1\text{-}C_6)$alkoxycarbonyl, cyano, nitro, or trifluoromethoxy;

provided at least two of R_a, R_b, R_c, and R_d are $-CH_2CH_2X$;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1 wherein R^1 is a group of formula (II):



(II)

wherein R_e is hydrogen, halo, $(C_1\text{-}C_6)$alkyl, halo$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkanoyloxy, cyano, nitro, or $(C_1\text{-}C_6)$alkylthio; and

wherein the benz ring is optionally substituted by one or more (e.g. 1, 2, 3, or 4) hydroxy, halo, $(C_1\text{-}C_6)$alkyl, halo$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkylthio; $(C_1\text{-}C_6)$alkanoyl, $(C_1\text{-}C_6)$alkanoyloxy, $(C_1\text{-}C_6)$alkoxycarbonyl, cyano, nitro, mercapto, trifluoromethoxy, or NR_fR_g;

wherein each R_f and R_g is independently hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkanoyl, phenyl, benzyl, or phenethyl; or R_f and R_g together with the nitrogen to which they are attached are pyrrolidino, piperidino or morpholino.

3-4. (Cancelled).

5. (Original) The compound of claim 1 wherein X is bromo, chloro, mesyl, trifluoromethylsulfonyl, or tosyl.

6. (Original) The compound of claim 1 wherein X is bromo.

7. (Original) The compound of claim 2 wherein R_c is hydrogen, halo, methyl, or methylthio.

8-11. (Cancelled).

12. (Original) The compound of claim 1 wherein R_a is $(C_1\text{-}C_6)$alkyl.

13. (Original) The compound of claim 1 wherein R_c is $(C_1\text{-}C_6)$alkyl.

14. (Original) The compound of claim 1 wherein R_a and R_b are each independently $-CH_2CH_2X$.

15. (Original) The compound of claim 1 wherein R_c, and R_d are each independently $-CH_2CH_2X$.

16. (Original) The compound of claim 1 wherein R_b and R_d are each independently $-CH_2CH_2X$.

17. (Original) The compound of claim 1 wherein R_a is methyl.

18. (Original) The compound of claim 1 wherein R_c is methyl.

19. (Original) The compound of claim 1 wherein R_a and R_b are each $-CH_2CH_2Br$.

20. (Original) The compound of claim 1 wherein R_c, and R_d are each $-CH_2CH_2Br$.

21. (Original) The compound of claim 1 wherein R_b and R_d are each $-CH_2CH_2Br$.

22. (Original) The compound of claim 1 wherein R_a and R_b are each independently $-CH_2CH_2Cl$.

23. (Original) The compound of claim 1 wherein R_c, and R_d are each independently $-CH_2CH_2Cl$.

24. (Original) The compound of claim 1 wherein R_b and R_d are each independently $-CH_2CH_2Cl$.

25. (Previously Presented) The compound of claim 1 which is:

2-(1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl) phosphorodiamidate;

2-(3-methyl-1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl) phosphorodiamidate;

2-(3-thiomethyl-1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl) phosphorodiamidate;

2-(3-bromo-1,4-naphthoquinonyl)methyl *N,N*-bis(2-chloroethyl) phosphorodiamidate;

2-(1,4-naphthoquinonyl)methyl *N,N*-bis(2-bromoethyl) phosphorodiamidate;

2-(3-methyl-1,4-naphthoquinonyl)methyl *N,N*-bis(2-bromoethyl) phosphorodiamidate;

2-(1,4-naphthoquinonyl)methyl bis[*N*-(2-chloroethyl)] phosphorodiamidate;

2-(1,4-naphthoquinonyl)methyl bis[*N*-methyl-*N*-(2-bromoethyl)]phosphorodiamidate;

2-(3-methyl-1,4-naphthoquinonyl)methyl bis[*N*-methyl-*N*-(2-bromoethyl)] phosphorodiamidate;

2-(1,4-naphthoquinonyl)methyl bis[*N*-methyl-*N*-(2-chloroethyl)] phosphorodiamidate;

or a pharmaceutically acceptable salt thereof.

26. (Cancelled).

27. (Original) A pharmaceutical composition comprising a compound of claim 1, in combination with a pharmaceutically acceptable diluent or carrier.

28. (Withdrawn) A therapeutic method for killing cancer cells or inhibiting their growth or proliferation comprising administering to a mammal in need of such therapy, an effective amount of a compound of claim 1.

29. (Withdrawn) The method of claim 28 wherein the cancer is a solid tumor.

30. (Cancelled).

31. (Currently amended) A method for preparing a compound of formula I as described in claim 1, wherein R^1 is a group of formula II



(II)

comprising oxidizing a corresponding compound of formula I wherein R^1 is a group of formula VI



(VI)

32. (New) The compound of claim 1, wherein the organic releasing group is capable of releasing a group of formula $-O-P(=O)(NR_aR_b)(NR_cR_d)$ *in vivo* from the compound of formula I.